ABC> Vol.4 No.4, June 2014

Influence of Therapy on Some Important Final Products of Oxidation of Lipids, Proteins and Nucleic Acids in Patients with Parkinson’s Diseases

DownloadDownload as PDF (Size:826KB)  HTML   XML  PP. 253-260  

ABSTRACT

The major clinical disturbances in Parkinson’s disease (PD) are consequence of dopamine depletion in the neostriatum, due to degeneration of dopaminergic neurons. The aim of the present study was to determine whether oxidative stress (OS) occurs during the clinical course of Parkinson’s disease and to evaluate the influence of therapy on the levels of some important final products of oxidation of lipids, proteins and nucleic acids in PD patients with drug therapy. For this purpose, we investigated the levels of malondialdehid (MDA), protein carbonyl content (PCC) and 8-hydroxy-2’-deoxyguanosine quantity (8-OHdG) in PD patients with and without drug therapy. The observed changes in MDA levels, PCC and 8-OHdG quantity in blood of untreated PD patients, suggested impaired antioxidant status and presence of oxidative stress in Parkinson disease. After treatment with Madopar, the elevation in by-products significantly progresses. Our results demonstrate that administration of Madopar causes in greater degree oxidative stress than that induced by Parkinson disease, by itself.

Cite this paper

Nikolova, G. , Grigorov, B. , Zheleva, A. and Gadjeva, V. (2014) Influence of Therapy on Some Important Final Products of Oxidation of Lipids, Proteins and Nucleic Acids in Patients with Parkinson’s Diseases. Advances in Biological Chemistry, 4, 253-260. doi: 10.4236/abc.2014.44031.

References

[1] Nagal, A. and Singla R.K. (2012) Parkinson’s Disease: Diagnosis, Therapeutics & Management. Webmed Central Pharmaceutical Sciences, 3, Article ID: WMC003670.
[2] Halliwell, B. (1992) Reactive Oxygen Species and the Central Nervous System. Journal of Neurochemistry, 59, 1609-1623.
http://dx.doi.org/10.1111/j.1471-4159.1992.tb10990.x
[3] Halliwell, B. and Chirico, S. (1993) Lipid Peroxidation: Its Mechanism, Measurement and Significance. The American Journal of Clinical Nutrition, 57, 715S-724S.
[4] Jolanta, D. and Wojciech, K. (2011) Oxidative DNA Damage and the Level of Biothiols, and L-Dopa Therapy in Parkinson’s Disease. In: Rana, A.Q., Ed., Etiology and Pathophysiology of Parkinson’s Disease, InTech, Chapter 16.
http://dx.doi.org/10.5772/18594
[5] Nikolova, G. and Mancheva, V. (2013) Analysis of the Parameters of Oxidative Stress in Patients with Parkinson’s Disease. Comparative Clinical Pathology, 22, 151-155.
http://dx.doi.org/10.1007/s00580-012-1407-8
[6] Cornetta, T., Palma, S., Aprile, I., Padua, L., Tonali, P., Testa, A. and Cozzi, R. (2009) Levodopa Therapy Reduces DNA Damage in Peripheral Blood Cells of Patients with Parkinson’s Disease. Cell Biology and Toxicology, 25, 321-330.
http://dx.doi.org/10.1007/s10565-008-9086-6
[7] Gilgun-Sherki, Y., Melamed, E. and Offen, D. (2001) Oxidative Stress Induced-Neurodegenerative Diseases: The Need for Antioxidants That Penetrate the Blood Brain Barrier. Neuropharmacology, 40, 959-975.
http://dx.doi.org/10.1016/S0028-3908(01)00019-3
[8] Lotharius, J. and Brundin, P. (2002) Pathogenesis of Parkinson’s Disease: Dopamine, Vesicles and α-Synuclein. Nature Reviews Neuroscience, 3, 932-942.
http://dx.doi.org/10.1038/nrn983
[9] Alam, Z.I., Daniel, S.E., Lees, A.J., Marsden, D.C., Jenner, P. and Halliwell, B. (1997) A Generalised Increase in Protein Carbonyls in the Brain in Parkinson’s But Not Incidental Lewy Body. Journal of Neurochemistry, 69, 1326-1329.
http://dx.doi.org/10.1046/j.1471-4159.1997.69031326.x
[10] Alam, Z.I., Jenner, A., Daniel, E., Lees, A.J., Cairns, N., Marsden, D., Jenner, P. and Halliwell, B. (1997) Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8-Hydroxyguanine Levels in Substantia Nigra. Journal of Neurochemistry, 69, 1196-1203.
http://dx.doi.org/10.1046/j.1471-4159.1997.69031196.x
[11] Kikuchi, A., Takeda, A., Onodera, H., Kimpara, T., Hisanaga, K., Sato, N., Nunomura, A., Castellani, R.J., Perry, G., Smith, M.A. and Itoyama, Y. (2002) Systemic Increase of Oxidative Nucleic Acid Damage in Parkinson’s Disease and Multiple System Atrophy. Neurobiology of Disease, 9, 244-248.
http://dx.doi.org/10.1006/nbdi.2002.0466
[12] Giammarioli, S., Filesi, C. and Sanzini, E. (1999) Oxidative Stress Markers: Specificity and Measurement Techniques. Annali-Istituto Superiore di Sanità, 35, 563-576.
[13] Gadjeva, V., Kuchukova, D. and Georgieva, R. (2005) Influence of Polychemotherapy on the Antioxidant Levels and Lipid Peroxidation in Patients with Lymphoproliferative Diseases. Comparative Clinical Pathology, 14, 13-18.
http://dx.doi.org/10.1007/s00580-005-0556-4
[14] Mahoney, J.J., Vreman, H.J., Stevenson, D.K. and Van Vessel, A.L. (1993) Measurements of Carboxyhaemoglobin by Five Spectrophotometers (Cooximeters) in Comparison with Reference Methods. Clinical Chemistry, 39, 1693.
[15] Sanyal, J., Bandyopadhyay, S.K., Banerjee, T.K., Mukherjee, SC, Chakraborty, D.P., Ray, B.C. and Rao, V.R. (2009) Plasma Levels of Lipid Peroxides in Patients with Parkinson’s Disease. Europ. European Review for Medical and Pharmacological Sciences, 13, 129-132.
[16] Gadjeva, V., Dimov, A. and Georgieva, N. (2008) Influence of Therapy on the Antioxidant Status in Patients with Melanoma. Journal of Clinical Pharmacy and Therapeutics, 33, 179-185.
http://dx.doi.org/10.1111/j.1365-2710.2008.00909.x
[17] Barnham, K.J., Masters, C.L. and Bush, A.I. (2004) Neurodegenerative Diseases and Oxidative Stress. Nature Reviews Drug Discovery, 3, 205-214.
http://dx.doi.org/10.1038/nrd1330
[18] Jenner, P. and Olanow, W. (1996) Oxidative Stress and the Pathogenesis of Parkinson’s Disease. Neurology, 47, 161-170.
http://dx.doi.org/10.1212/WNL.47.6_Suppl_3.161S
[19] Sudha, K., Rao, A., Rao, S. and Rao, A. (2003) Free Radical Toxicity and Antioxidants in Parkinson’s Disease. Neurology India, 51, 60.
[20] Rio, D.D., Stewart, A.J. and Pellegrini, N. (2005) A Review of Recent Studies on Malondialdehyde as Toxic Molecule and Biological Marker of Oxidative Stress. Nutrition, Metabolism & Cardiovascular Diseases, 15, 316-328.
http://dx.doi.org/10.1016/j.numecd.2005.05.003
[21] de Zwart, L.L., Meerman, J.H.N., Commandeur, J.N.M. and Vermeulen, N.P.E. (1999) Biomarkers of Free Radical Damage. Applications in Experimental Animals and in Human. Free Radical Biology and Medicine, 26, 202-226.
http://dx.doi.org/10.1016/S0891-5849(98)00196-8
[22] Dexter, D.T., Carter, C., Agid, F., Lees, A.J., Jenner, P. and Marsden, C.D. (1986) Lipid Peroxidation as a Cause of Nigral Cell Death in Parkinson Disease. The Lancet, 2, 639-640.
http://dx.doi.org/10.1016/S0140-6736(86)92471-2
[23] Davies K.J. and Delsignore M.E. (1987) Protein Damage and Degradation by Oxygen Radicals. III. Modification of Secondary and Tertiary Structure. Journal of Biological Chemistry, 262, 9908-9913.
[24] Hawkins, C.L. and Morgan, P.E. (2009) Quantification of Protein Modification by Oxidants. Free Radical Biology and Medicine, 46, 965-988.
http://dx.doi.org/10.1016/j.freeradbiomed.2009.01.007
[25] Stadtman, E.R. (1992) Protein Oxidation and Aging. Science, 257, 1220-1224.
http://dx.doi.org/10.1126/science.1355616
[26] Yoritaka, A., Hattori, N., Uchida, K., Tanaka, M., Stadtman, E.R. and Mizuno, Y. (1996) Immunohistochemical Detection of 4-Hydroxynonenal Protein Adducts in Parkinson Disease. Proceedings of the National Academy of Sciences of the United States of America, 93, 2696-2701.
http://dx.doi.org/10.1073/pnas.93.7.2696
[27] Youdim, M.B., Drigues, N. and Mandelm S. (2001) Oxidative Stress Indices in Parkinson’s Disease. In: Mouradian, M.M., Ed., Parkinson’s disease, Humana Press, New York, 137-153.
http://dx.doi.org/10.1385/1-59259-142-6:137
[28] Dalle-Donne, I., Giustarini, D., Colombo, R., Rossi, R. and Milzani, A. (2003) Protein Carbonylation in Human Diseases. Trends in Molecular Medicine, 9, 169-176.
http://dx.doi.org/10.1016/S1471-4914(03)00031-5
[29] Davies, K.J. and Goldberg, A.L. (1987) Proteins Damaged by Oxygen Radicals Are Rapidly Degraded in Extracts of Red Blood Cells. Journal of Biological Chemistry, 262, 8227-8234.
[30] Nyström, T. (2005) Role of Oxidative Carbonylation in Protein Quality Control and Senescence. The EMBO Journal, 24, 1311-1317.
http://dx.doi.org/10.1038/sj.emboj.7600599
[31] Levine, R.L. (2002) Carbonyl Modified Proteins in Cellular Regulation, Aging, and Disease. Free Radical Biology and Medicine, 32, 790-796.
http://dx.doi.org/10.1016/S0891-5849(02)00765-7
[32] Rivett, A.J. and Levine, R.L. (1990) Metal-Catalyzed Oxidation of Escherichia coli Glutamine Synthetase: Correlation of Structural and Functional Changes. Archives of Biochemistry and Biophysics, 278, 26-34.
http://dx.doi.org/10.1016/0003-9861(90)90226-O
[33] Beal, M.F. (2002) Oxidatively Modified Proteins in Aging and Disease. Free Radical Biology and Medicine, 32, 797-803.
http://dx.doi.org/10.1016/S0891-5849(02)00780-3
[34] Deans, S.G., Noble, R.C., Penzes L. and Imre, S.G. (1993) Promotional Effects of Plant Volatile Oils on the Polyunsaturated Fatty Acid Status during Aging. Age, 16, 71-74.
http://dx.doi.org/10.1007/BF02435040
[35] Lyras, L., Evans, P.J., Shaw, P.J., Ince, P.G. and Halliwell, B. (1996) An Assessment of Oxidative Damage to Proteins, Lipids, and DNA in Brain from Patients with Alzheimer’s Disease. Free Radical Research, 24, 397-406.
[36] Smith, J.F., Hardcastle, J.D., Denton, G., Alderson, D., Grase, R.H., Mansi, J.L., Yosef, H.M., Nordle, O., Lauri, H. and Wahlby, S. (1995) Two Phase III Trials of Tauromustine (TCNU) in Advanced Colorectal Cancer. Annals of Oncology, 6, 948-949.
[37] Fahn, S. and the Parkinson Study Group (2005) Does Levodopa Slow or Hasten the Rate of Progression of Parkinson’s Disease? Journal of Neurology, 252, IV/37-IV/42.
[38] Spencer, J.P.E., Jenner, A., Butler, J., Aruoma, I., Dexter, D.T., Jenner, P. and Halliwell, B. (1996) Oxidative DNA-Damage in Human Respiratory-Tract Epithelial-Cells—Time-Course in Relation to DNA Strand Breakage. Free Radical Research, 24, 95-105.
[39] Quintero, J.E., Wang, X. and Zhang, Z. (2011) Developing an MRI-Based Biomarker for Early Diagnosis of Parkinson’s Disease. InTech.
http://dx.doi.org/10.5772/18458
[40] Melo, A., Monteiro, L., Lima, R.M.F., de Oliveira, D.M., de Cerqueira, M.D. and El-Bachá, R.S. (2011) Oxidative Stress in Neurodegenerative Diseases: Mechanisms and Therapeutic Perspectives. Oxidative Medicine and Cellular Longevity, 2011, Article ID: 467180.
http://dx.doi.org/10.1155/2011/467180
[41] Isobe, C., Abe, T. and Terayama, Y. (2010) Levels of Reduced and Oxidized CoenzymeQ-10 and 8-hydroxy-2-deoxyguanosine in the Cerebrospinal Fluid of Patients with Living Parkinson’s Disease Demonstrate That Mitochondrial Oxidative Damage and/or Oxidative DNA Damage Contributes to the Neurodegenerative Process. Neuroscience Letters, 469, 159-163.
http://dx.doi.org/10.1016/j.neulet.2009.11.065
[42] Floor, E. and Wetzel, M.G. (1998) Increased Protein Oxidation in Human Substantia Nigra Pars Compacta in Comparison with Basal Ganglia and Prefrontal Cortex Measured with an Improved Dinitrophenylhydrazine Assay. Journal of Neurochemistry, 70, 268-275.
http://dx.doi.org/10.1046/j.1471-4159.1998.70010268.x
[43] Prigione, A., Begni, B., Galbussera, A., Beretta, S., Brighina, L., Garofalo, R., Andreoni, S., Piolti, R. and Ferrarese, C. (2006) Oxidative Stress in Peripheral Blood Mononuclear Cells from Patients with Parkinson’s Disease: Negative Correlation with Levodopa Dosage. Neurobiology of Disease, 23, 36-43.
http://dx.doi.org/10.1016/j.nbd.2006.01.013
[44] Sato, S., Mizuno, Y. and Hattori, U. (2005) Urinary 8-Hydroxydeoxyguanosine Levels as a Biomarker for Progression of Parkinson Disease. Neurolog, 64, 1081-1083.
http://dx.doi.org/10.1212/01.WNL.0000154597.24838.6B
[45] Florczak, J., Dorszewska, J. and Kozubski, W. (2008) Influence of L-Dopa Treatment Duration on the Level of Oxidative Damage to DNA and Thiol Compound Concentration in Patients with Parkinson’s Disease. Neurologia i Neurochirurgia Polska, 42, S36-S44.
[46] Parkinson Study Group (2004) Pramipexole vs Levodopa as Initialtreatment for Parkinson Disease—A 4-Year Randomized Controlled Trial. Archives of Neurology, 61, 1044-1053.
[47] Halliwell, B. (2001) Role of Free Radicals in the Neurodegenerative Diseases: Therapeutic Implications for Antioxidant Treatment. Drugs & Aging, 18, 685-716.
http://dx.doi.org/10.2165/00002512-200118090-00004
[48] Halliwell, B. (2006) Oxidative Stress and Neurodegeneration: Where Are We Now? Journal of Neurochemistry, 97, 1634-1658.
http://dx.doi.org/10.1111/j.1471-4159.2006.03907.x
[49] Lan, J., Henshall, D.C., Simon, R.P. and Chen, J. (2000) Formation of the Base Modification 8-Hydroxyl-2’-Deoxyguanosine and DNA Fragmentation Following Seizures Induced by Systemic Kainic Acid in the Rat. Journal of Neurochemistry, 74, 302-309.
http://dx.doi.org/10.1046/j.1471-4159.2000.0740302.x

  
comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.